Results from a phase I study of continuous infusion cladribine, high-dose cytarabine, and mitoxantrone for relapsed/refractory high-grade myeloid neoplasms

Leuk Lymphoma. 2023 May;64(5):1057-1059. doi: 10.1080/10428194.2023.2185087. Epub 2023 Mar 9.

Authors

Noam E Kopmar¹, Ted Gooley², Niall Curley¹, Kathryn Russell¹, Carole Shaw³, Kelda Schonhoff¹, John Lim¹, Anna B Halpern^{1

3}, Roland B Walter^{1

3

4

5}, Bart L Scott^{1

3}, Jacob Appelbaum¹, Paul C Hendrie¹, Elihu H Estey^{1

3}, Mary-Elizabeth M Percival^{1

3}

Affiliations

¹ Department of Medicine, University of Washington, Seattle, WA, USA.
² Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
³ Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
⁴ Department of Laboratory Medicine & Pathology, University of Washington, Seattle, WA, USA.
⁵ Department of Epidemiology, University of Washington, Seattle, WA, USA.

No abstract available

Publication types

Clinical Trial, Phase I
Letter
Research Support, N.I.H., Extramural

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / adverse effects
Cladribine
Cytarabine
Humans
Leukemia, Myeloid, Acute* / drug therapy
Mitoxantrone*
Neoplasm Recurrence, Local / drug therapy

Substances

Mitoxantrone
Cladribine
Cytarabine

Grants and funding